Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR VIII
EGFR VIII - Associated Disease
- brain glioma
- Source Database
- CIViC Evidence
- Description
- Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1017
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/312
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Brain Glioma
- Evidence Direction
- Supports
- Drug
- Nimotuzumab
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26778701
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Nimotuzumab | Sensitivity | true |